Premium
Neoadjuvant intra‐arterial chemotherapy in advanced laryngeal and hypopharyngeal cancer
Author(s) -
Gupta Pankaj,
Bhalla Ashu Seith,
Thulkar Sanjay,
Kumar Atin,
Mohanti Bidhu Kalyan,
Thakar Alok,
Sharma Atul,
Vishnubhatla Sreenivas
Publication year - 2016
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12123
Subject(s) - medicine , hypopharyngeal cancer , superior thyroid artery , chemotherapy , interim analysis , radiation therapy , chemoradiotherapy , stage (stratigraphy) , cisplatin , oncology , interim , surgery , radiology , randomized controlled trial , thyroid , history , paleontology , archaeology , biology
Aim To investigate whether neoadjuvant intra‐arterial chemotherapy down‐stages the tumors and predicts ultimate outcome in patients with advanced laryngeal and hypopharyngeal cancer. Methods Fifteen patients with stage III and IV cancers received two cycles of intra‐arterial cisplatin (40 mg/m 2 ) at days 1 and 15, infused super‐selectively into superior thyroid artery. Interim evaluation using RECIST 1.1 and volumetry was done in all patients at day 25. Subsequently, the patients received concurrent chemoradiotherapy or surgery with radiotherapy. Final evaluation was done in 10 patients. Results At interim evaluation, five patients qualified as responders. Partial response, stable disease and progressive disease rates were 40, 33 and 27%, respectively. At final evaluation, complete response was noted in all patients. Conclusions At interim evaluation, the response rates were lower compared to intravenous neoadjuvant chemotherapy and response to intra‐arterial chemotherapy did not predict the ultimate outcome. Thus neoadjuvant intra‐arterial chemotherapy offers no advantage over concurrent chemoradiotherapy.